

Japan Rare Disease Patient Identification Services Market - 2024-2033

<https://marketpublishers.com/r/JB9339765387EN.html>

Date: February 2026

Pages: 186

Price: US\$ 2,999.00 (Single User License)

ID: JB9339765387EN

Abstracts

The Japan Rare Disease Patient Identification Services Market was valued at US\$ 40 Million in 2024 and is anticipated to reach US\$ 110.92 Million by 2033, at a CAGR of 0.12 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan Rare Disease Patient Identification Services Market.

This report delivers a comprehensive overview of the Japan Rare Disease Patient Identification Services Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Rare Disease Patient Identification Services Market. The Japan Rare Disease Patient Identification Services Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan Rare Disease Patient Identification Services Market Scope:

By Service Type

Patient Recruitment & Registry Services

Patient Screening & Eligibility Assessment

Patient Engagement & Retention Solutions

Digital Outreach & Analytics Platforms

By Disease Focus

Rare Genetic Disorder Conditions

Rare Neurological & Neuromuscular Conditions

Rare Oncology

Other Rare Conditions

By Method

Registry-Based Identification

Genetic & Genomic Testing Support

AI / Data Analytics Platforms

Digital & Telehealth Screening

By End User

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROs)

On-Site-Based Services & Remote Services

Diagnostic Laboratories

By Mode of Delivery

On-Site-Based Services

Remote Services

Hybrid Models

Key Players

IQVIA

CMIC HOLDINGS Co., LTD.

Parexel International (MA) Corporation.

Eisai Co., Ltd.

Buzzreach Inc.

Linical Co., Ltd.

DCT JAPAN

Major Highlights

This report delivers a comprehensive overview of the Japan Rare Disease Patient Identification Services Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Rare Disease Patient Identification Services Market. The Japan Rare Disease Patient Identification Services Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Advances in Genomic and Diagnostic Technologies
 - 3.1.1.2. Growing Focus on Rare Genetic Disorders
 - 3.1.1.3. Increasing Collaboration Across Stakeholders
 - 3.1.2. Restraints
 - 3.1.2.1. Limited Access to Specialized Testing
 - 3.1.2.2. Underdiagnosis and Data Gaps
 - 3.1.3. Opportunity
 - 3.1.3.1. Expansion of Digital Health and AI Tools
 - 3.1.3.2. Growing Rare Disease Awareness Campaigns
 - 3.1.3.3. Growth in Clinical Trial Support Services
 - 3.1.4. Trends
 - 3.1.4.1. Use of National Databases and Registries
 - 3.1.4.2. Integration with Clinical Trials
 - 3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

- 4.1. Porter's Five Force Analysis – Japan Rare Disease Patient Identification Services
- 4.2. Geopolitical & Supply Chain Exposure
- 4.3. Social & Patient-Centric Factors
- 4.4. Economic Factors
- 4.5. Pricing Analysis
- 4.6. Regulatory Analysis
- 4.7. Go-To-Market (GTM) Strategy
- 4.8. Innovation & R&D Trends
- 4.9. Sustainability and ESG Analysis
- 4.10. Key Service Providers and Market Participants
- 4.11. Buyer Decision Criteria & Adoption Drivers
- 4.12. DMI Opinion – Strategic Outlook for the Japan Rare Disease Patient Identification Services Market

5. BY SERVICE TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
 - 5.1.2. Market Attractiveness Index, By Service Type
- 5.2. Patient Recruitment & Registry Services*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Patient Screening & Eligibility Assessment
- 5.4. Patient Engagement & Retention Solutions
- 5.5. Digital Outreach & Analytics Platforms

6. BY DISEASE FOCUS

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Focus
 - 6.1.2. Market Attractiveness Index, By Disease Focus
- 6.2. Rare Genetic Disorder Conditions*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Rare Neurological & Neuromuscular Conditions
- 6.4. Rare Oncology

6.5. Other Rare Conditions

7. BY METHOD

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method

7.1.2. Market Attractiveness Index, By Method

7.2. Registry-Based Identification*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Genetic & Genomic Testing Support

7.4. AI / Data Analytics Platforms

7.5. Digital & Telehealth Screening

8. BY END USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

8.1.2. Market Attractiveness Index, By End User

8.2. Pharmaceutical & Biotechnology Companies*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Contract Research Organizations (CROs)

8.4. On-Site-Based Services & Remote Services

8.5. Diagnostic Laboratories

9. BY MODE OF DELIVERY

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery

9.1.2. Market Attractiveness Index, By Mode of Delivery

9.2. On-Site-Based Services*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Remote Services

9.4. Hybrid Models

10. COMPETITIVE LANDSCAPE ANALYSIS

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 10.4. Partner Identification Analysis
- 10.5. Investment & Funding Landscape
- 10.6. Strategic Alliances & Innovation Pipelines

11. COMPANY PROFILES

- 11.1. IQVIA*
 - 11.1.1. Company Overview
 - 11.1.2. Service Type Portfolio
 - 11.1.3. Revenue Analysis
 - 11.1.4. Pricing Analysis
 - 11.1.5. SWOT Analysis
 - 11.1.6. Recent Developments
 - 11.1.6.1. Major Deals
 - 11.1.6.2. M&A
 - 11.1.6.3. Collaboration
 - 11.1.6.4. Acquisition
 - 11.1.6.5. Joint Ventures
 - 11.1.6.6. Innovations
 - 11.1.7. Recent News
 - 11.1.7.1. Events
 - 11.1.7.2. Conferences
 - 11.1.7.3. Symposiums
 - 11.1.7.4. Webinars
- 11.2. CMIC HOLDINGS Co., LTD.
- 11.3. Parexel International (MA) Corporation.
- 11.4. Eisai Co., Ltd.
- 11.5. Buzzreach Inc.
- 11.6. Linical Co., Ltd.
- 11.7. DCT JAPAN (LIST NOT EXHAUSTIVE)

12. JAPAN RARE DISEASE PATIENT IDENTIFICATION SERVICES MARKET – RESEARCH METHODOLOGY

- 12.1. Research Data
 - 12.1.1. Secondary Data

- 12.1.2. Primary Data
- 12.1.3. CAGR Analysis
- 12.2. Market Size Estimation Methodology
 - 12.2.1. Bottom-Up Approach
 - 12.2.2. Top-Down Approach
- 12.3. Market Breakdown & Data Triangulation
- 12.4. Research Assumptions
- 12.5. Limitations

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

I would like to order

Product name: Japan Rare Disease Patient Identification Services Market - 2024-2033

Product link: <https://marketpublishers.com/r/JB9339765387EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JB9339765387EN.html>